where does glp 1 drug come from GLP-1 and the kidney: physiology to pharmacology and outcomes in diabetes Scientists cautiously suggest GLP-1s are
Description
1 Patients on concomitant insulin therapies or insulin secretagogues are at a higher risk for this adverse event
Knerr PJ, Mowery SA, Douros JD, et al
Compared to the past, this not only affects adults but also numerous children and young people
As a result, diabetes is now the leading cause of end-stage kidney disease in Western countries
Among them, anti-obesity drugs have high compliance rates and cause noticeable short-term effects in reducing obese levels
Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis
